EEHTA-CEIS, DEF Department, Faculty of Economics, University of Rome "Tor Vergata", 00133 Rome, Italy.
Institute for Leadership and Management in Health, Kingston University, London KT1 2EE, UK.
Int J Environ Res Public Health. 2021 Aug 26;18(17):9005. doi: 10.3390/ijerph18179005.
Breast cancer is the most prevalent cancer affecting women and it represents an important economic burden. The aim of this study was to estimate the socio-economic burden of breast cancer (BC) in Italy both from the National Health Service (NHS) and the government perspectives (costs borne by the social security system).
The economic analysis was based on the costs incurred by the NHS from 2008 to 2016 (direct costs related to hospitalizations) and by the National Social Security Institute (INPS) from 2009 to 2015 (costs of social security benefits) for patients with breast cancer. The analysis was based on the Hospital Information System (HIS) and Disability Insurance Awards databases. For both databases, patients affected by a malignant neoplasm of the female breast, carcinoma in situ, or secondary malignant neoplasm of the breast were considered.
Results show that more than 75,000 women were hospitalized for breast cancer every year, with an overall cost for hospitalization of about €300 million per year. From the Social Security analysis, a number of 29,000 beneficiaries each year was estimated. Considering per patient social costs, breast cancer at the primary stage cost €8828 per year, while secondary neoplasms cost €9780, with an average total economic burden of €257 million per year.
This analysis focused on the economic impact of breast cancer in Italy, showing that an advanced stage of the disease was associated with a higher cost.
乳腺癌是影响女性的最常见癌症,也是一个重要的经济负担。本研究旨在从国家卫生服务(NHS)和政府角度(社会保障系统承担的成本)评估意大利乳腺癌(BC)的社会经济负担。
经济分析基于 NHS 从 2008 年至 2016 年(与住院相关的直接成本)和国家社会保障研究所(INPS)从 2009 年至 2015 年(社会保障福利成本)为乳腺癌患者产生的成本。分析基于医院信息系统(HIS)和残疾保险奖励数据库。对于这两个数据库,都考虑了患有女性乳房恶性肿瘤、原位癌或乳房继发性恶性肿瘤的患者。
结果表明,每年有超过 75,000 名女性因乳腺癌住院,每年的住院总费用约为 3 亿欧元。从社会保障分析来看,每年估计有 29,000 名受益人。考虑到每位患者的社会成本,原发性乳腺癌每年的费用为 8828 欧元,而继发性肿瘤的费用为 9780 欧元,每年的平均总经济负担为 2.57 亿欧元。
本分析重点关注了意大利乳腺癌的经济影响,表明疾病的晚期阶段与更高的成本相关。